Literature DB >> 6439588

myo-Inositol and sorbitol in erythrocytes from diabetic patients before and after sorbinil treatment.

C Popp-Snijders, M Z Lomecky-Janousek, J A Schouten, E A van der Veen.   

Abstract

Erythrocytes from diabetic patients before and after treatment with the aldose reductase inhibitor, sorbinil, were analyzed by a capillary gas chromatographic method for sorbitol and myo-inositol. The mean erythrocyte sorbitol level in the diabetic patients was significantly higher than in the control subjects (13.1 +/- 0.9 and 5.2 +/- 0.3 nmol/ml erythrocytes, respectively, mean +/- SEM, p less than 0.001). The mean erythrocyte myo-inositol level in diabetic patients was not different from that in control subjects (43.2 +/- 2.9 and 40.5 +/- 1.9 nmol/ml erythrocytes, respectively). Sorbinil treatment reduced the elevated sorbitol levels in the diabetic patients to normal or slightly below normal, but did not affect the erythrocyte myo-inositol concentration. It is concluded that the erythrocyte is not a suitable model to monitor a possible effect of sorbinil on myo-inositol concentration in less accessible tissues.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6439588     DOI: 10.1007/bf00290386

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  20 in total

Review 1.  The sorbitol pathway and the complications of diabetes.

Authors:  K H Gabbay
Journal:  N Engl J Med       Date:  1973-04-19       Impact factor: 91.245

2.  Prevention of defects of axonal transport and nerve conduction velocity by oral administration of myo-inositol or an aldose reductase inhibitor in streptozotocin-diabetic rats.

Authors:  J H Mayer; D R Tomlinson
Journal:  Diabetologia       Date:  1983-11       Impact factor: 10.122

3.  Kinetics of an orally absorbed aldose reductase inhibitor, sorbinil.

Authors:  G Foulds; M M O'Brien; J R Bianchine; K H Gabbay
Journal:  Clin Pharmacol Ther       Date:  1981-11       Impact factor: 6.875

4.  Determination of sorbitol in erythrocytes of diabetic and healthy subjects by capillary gas chromatography.

Authors:  C Popp-Snijders; M Z Lomecky; A P de Jong
Journal:  Clin Chim Acta       Date:  1983-07-31       Impact factor: 3.786

5.  Polyol pathway activity and myo-inositol metabolism. A suggested relationship in the pathogenesis of diabetic neuropathy.

Authors:  D Finegold; S A Lattimer; S Nolle; M Bernstein; D A Greene
Journal:  Diabetes       Date:  1983-11       Impact factor: 9.461

6.  Myo-inositol and sorbitol metabolism in relation to peripheral nerve function in experimental diabetes in the rat: the effect of aldose reductase inhibition.

Authors:  K R Gillon; J N Hawthorne; D R Tomlinson
Journal:  Diabetologia       Date:  1983-10       Impact factor: 10.122

7.  Red blood cell sorbitol as an indicator of polyol pathway activity. Inhibition by sorbinil in insulin-dependent diabetic subjects.

Authors:  J I Malone; H Leavengood; M J Peterson; M M O'Brien; M G Page; C E Aldinger
Journal:  Diabetes       Date:  1984-01       Impact factor: 9.461

8.  Oral supplementation of myoinositol: effects on peripheral nerve function in human diabetics and on the concentration in plasma, erythrocytes, urine and muscle tissue in human diabetics and normals.

Authors:  G Gregersen; B Bertelsen; H Harbo; E Larsen; J R Andersen; A Helles; M Schmiegelow; J E Christensen
Journal:  Acta Neurol Scand       Date:  1983-03       Impact factor: 3.209

9.  Sorbitol and myoinositol levels in the cerebrospinal fluid of diabetic patients.

Authors:  C Servo
Journal:  Acta Endocrinol Suppl (Copenh)       Date:  1980

10.  Glycosylated hemoglobins and long-term blood glucose control in diabetes mellitus.

Authors:  K H Gabbay; K Hasty; J L Breslow; R C Ellison; H F Bunn; P M Gallop
Journal:  J Clin Endocrinol Metab       Date:  1977-05       Impact factor: 5.958

View more
  2 in total

1.  Peripheral nerve function in relation to quality of metabolic control in diabetes.

Authors:  F W Bertelsmann; J J Heimans; J C van Rooy; C Popp-Snijders; E A van der Veen
Journal:  J Neurol       Date:  1987-06       Impact factor: 4.849

Review 2.  The efficacy of aldose reductase inhibitors in the management of diabetic complications. Comparison with intensive insulin treatment and pancreatic transplantation.

Authors:  J M van Gerven; A M Tjon-A-Tsien
Journal:  Drugs Aging       Date:  1995-01       Impact factor: 3.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.